Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indian pharma firm Lupin along with its subsidiary Lupin Pharmaceuticals have resolved its dispute against Medicis Pharmaceutical over Solodyn (minocycline HCI, USP) Extended Release Tablets.
Subscribe to our email newsletter
Following this settlement, Lupin is now eligible for selling the generic versions of Solodyn in 45mg, 90mg, and 135mg strengths under a license from Medicis commencing November 2011, or earlier under certain conditions.
The settlement also allows Lupin to sell the generic versions of Solodyn in 65mg and 115mg strengths
under a license from Medicis effective in February 2018.
Additionally, with this settlement Lupin is also eligible for selling generic versions of Solodyn in 55mg, 80mg and 105mg strengths as per a license from Medicis effective in February 2019.